Previous 10 | Next 10 |
home / stock / cdxs / cdxs articles
Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for R...
BEVERLY, Mass. and REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- seqWell, a global provider of genomic library workflow solutions, and...
Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a pot...
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected f...
Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Moto...
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it wi...
STAMFORD, Conn., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Codexis, Inc. (NASDAQ:CDXS) ("Codexis" or the "Company") ...
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that ...
REDWOOD CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced a pre...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...